John R Murren

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule
    J R Murren
    Yale Cancer Center, New Haven, Connecticut, USA
    Oncology (Williston Park) 15:25-30. 2001
  2. ncbi request reprint Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer
    John R Murren
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 4:1311-5. 2005
  3. ncbi request reprint Phase I study of perillyl alcohol in patients with refractory malignancies
    John R Murren
    Departments of Medicine, Pharmacology, Obstetrics and Gynecology, Cancer Center, Yale University School of Medicine, 333 Cedar St, NSB 287, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:130-5. 2002
  4. ncbi request reprint Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
  5. ncbi request reprint Camptothecin and taxane regimens for small-cell lung cancer
    Myron S Kwong
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Oncology (Williston Park) 16:33-8. 2002
  6. ncbi request reprint A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer
    Erole M Hobdy
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 3:89-93. 2004
  7. ncbi request reprint Angiogenesis in non-small cell lung cancer. A new target for therapy
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Am J Respir Med 1:325-38. 2002
  8. ncbi request reprint Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P O Box 208032, 333 Cedar Str 287 NSB, New Haven, CT 06520 8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
  9. ncbi request reprint Therapy for stage IIIB and stage IV non-small cell lung cancer
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Chest Med 23:209-24. 2002
  10. ncbi request reprint Erlotinib OSI/Roche/Genentech
    Tracy E Kim
    Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Curr Opin Investig Drugs 3:1385-95. 2002

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule
    J R Murren
    Yale Cancer Center, New Haven, Connecticut, USA
    Oncology (Williston Park) 15:25-30. 2001
    ..The most common nonhematologic toxicities remain asthenia, neuropathy, and diarrhea. Future studies will explore and better define the role of these drug combinations in the treatment of lung cancer...
  2. ncbi request reprint Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer
    John R Murren
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 4:1311-5. 2005
    ..We conducted a phase II study to evaluate the efficacy and safety of the combination of irinotecan and paclitaxel in patients with advanced stage non-small cell lung cancer (NSCLC)...
  3. ncbi request reprint Phase I study of perillyl alcohol in patients with refractory malignancies
    John R Murren
    Departments of Medicine, Pharmacology, Obstetrics and Gynecology, Cancer Center, Yale University School of Medicine, 333 Cedar St, NSB 287, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:130-5. 2002
    ..Further development of perillyl alcohol on this schedule would be facilitated by reformulation of the capsule...
  4. ncbi request reprint Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
    ..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers...
  5. ncbi request reprint Camptothecin and taxane regimens for small-cell lung cancer
    Myron S Kwong
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Oncology (Williston Park) 16:33-8. 2002
    ..The combination of taxanes and irinotecan holds promise as an active regimen that may be tolerated better than cisplatin and irinotecan...
  6. ncbi request reprint A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer
    Erole M Hobdy
    Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Cancer Biol Ther 3:89-93. 2004
    ..We conducted a multicenter phase II study to evaluate the efficacy and safety of the combination of topotecan and cyclophosphamide for patients with advanced small cell lung cancer (SCLC)...
  7. ncbi request reprint Angiogenesis in non-small cell lung cancer. A new target for therapy
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Am J Respir Med 1:325-38. 2002
    ....
  8. ncbi request reprint Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P O Box 208032, 333 Cedar Str 287 NSB, New Haven, CT 06520 8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
    ..Novel molecular targeted therapies are among the strategies currently being investigated in SCLC...
  9. ncbi request reprint Therapy for stage IIIB and stage IV non-small cell lung cancer
    Tracy E Kim
    Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Chest Med 23:209-24. 2002
    ..Many of these novel target modulators likely will require combination with conventional chemotherapy for optimal results...
  10. ncbi request reprint Erlotinib OSI/Roche/Genentech
    Tracy E Kim
    Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    Curr Opin Investig Drugs 3:1385-95. 2002
    ..In October 2001, phase III monotherapy trials in NSCLC and phase III combination trials in pancreatic cancer were also initiated [426704]. In Japan, the compound was in phase I studies in January 2002 [439189]...
  11. ncbi request reprint Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel
    Vanita Noronha
    Section of Medical Oncology, Yale Comprehensive Cancer Center, 333 Cedar Street, PO Box 208032, New Haven, CT 06520 8032, USA
    Lancet Oncol 7:270-1. 2006

Research Grants2

  1. Radioisotope Therapy Targeting the Somatostatin Receptor
    Gina Chung; Fiscal Year: 2003
    ..These translational studies will serve as the basis for expanding a novel therapeutic modality for neuroendocrine cancers. ..
  2. Improved Use of Camptothecins for Small Cell Lung Cancer
    John Murren; Fiscal Year: 2004
    ..The data generated by these studies will provide additional insight into clinically relevant mechanisms of resistance to camptothecin that occur in SCLC. ..